Chad Brummett is the Director of the Division of Pain Research and the Director of Clinical Research in the Department of Anesthesiology. His interests include predictors of chronic post-surgical pain as well as failure to derive benefit from interventions and surgeries done primarily for pain. He also leads an institution-wide initiative to create a biorepository for research of genetic factors associated with the development of disease and response to treatment. In addition, Dr. Brummett was the first to describe the use of peripheral perineural dexmedetomidine, and his early research focused on the efficacy, safety, and mechanisms of dexmedetomidine added to local anesthetics for peripheral nerve blocks. He has since translated that work to humans.
Amy S.B. Bohnert is a mental health services researcher with training in public health who focuses her research on epidemiology and brief interventions regarding substance use and related disorders. Within a team of collaborators at the University of Michigan and the Department of Veterans Affairs, she has led a number of projects related to overdose and prescription drug safety. A number of her research activities have been specifically aimed at improving care occurring in substance use disorder treatment settings. Dr. Bohnert has demonstrated a particular expertise in applying epidemiology methods to the analysis of electronic health records-based datasets to answer important questions for health services delivery. Dr. Bohnert earned her PhD in Public Health at Johns Hopkins University and completed her postdoctoral fellowship with the Department of Veterans Affairs, National Serious Mental Illness Treatment Research and Evaluation Center in Ann Arbor, MI. She has an appointment as an Associate Professor in the Department of Psychiatry at the University of Michigan.
Use Case: Precision Opioid Prescribing
Precision Health at the University of Michigan will support a variety of precision-related research projects — across a broad spectrum of disciplines — occurring at U-M. Our focus on opioid prescribing in the pre-surgical setting presents a use case that will allow us to test and refine the resources and infrastructure that will be most useful to researchers—knowledge that we will apply to the additional projects Precision Health will undertake in 2018.
Opioid misuse is a serious public health crisis that’s been sweeping across the United States. Currently, 78 Americans die each day due to opioid-related overdoses. The vast majority of individuals who become dependent on prescription opioids receive their first dose following surgical care. Precision Health at the University of Michigan is focusing on understanding the factors that put people at risk of long-term opioid use so that these patients can be prescribed alternative pain management strategies when having surgery.
An important resource Precision Health will draw on for this use case is the Michigan Opioid Prescribing Engagement Network (Michigan-OPEN). Led by U-M researchers, Michigan OPEN aims to ensure appropriate acute pain care following surgery, while protecting patients and communities by raising awareness about opioid misuse and creating interventions that reduce postoperative opioid prescribing and patient consumption.
The Michigan Genomics Initiative (MGI) is another valuable data resource that will inform Precision Health’s work on precision opioid prescribing. Containing health information from 50,000 subjects, MGI is an institutional repository of DNA and genetic and phenotypic data for future medical research. MGI is committed to advancing the understanding of health, wellness, and the development of disease; to predicting response to treatments; and to advancing drug development.